![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 29, 26422-26428, July 19, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Neurology, University of Crete, School of Health Sciences, Section of Medicine, Heraklion, 71500 Crete, Greece
Received for publication, January 2, 2002, and in revised form, April 6, 2002
| |
ABSTRACT |
|---|
|
|
|---|
Human glutamate dehydrogenase (GDH) exists in two
isoforms encoded by the GLUD1 and GLUD2 genes,
respectively. Although the two enzymes share in their mature form all
but 15 of their 505 amino acids, they differ markedly in their
allosteric regulation. To identify the structural basis for these
allosteric characteristics, we performed site-directed mutagenesis on
the human GLUD1 gene at sites that differ from the
GLUD2 gene using a cloned GLUD1 cDNA.
Results showed that substitution of Ala for Gly-456, but not
substitution of His for Arg-470 or Ser for Asn-498, renders the enzyme
markedly resistant to GTP inhibition (IC50 = 2.80 µM) as compared with the wild type
GLUD1-derived GDH (IC50 = 0.19 µM). The G456A mutation abolished the cooperative
behavior of the enzyme, as revealed by the GTP inhibitory curves. The
catalytic and kinetic properties of the G456A mutant and its activation by ADP were comparable with those of the wild type GDH. Gly-456 lies in
a very tightly packed region of the GDH molecule, and its replacement
by Ala may lead to steric clashes with neighboring amino acids. These,
in turn, may affect the conformational state of the protein that is
essential for the allosteric regulation of the enzyme by GTP.
Glutamate dehydrogenase
(GDH)1 (E.C.1.4.1.3)
catalyzes the reversible oxidative deamination of glutamate to
GDH in humans exists in two different isoforms: a housekeeping and a
nerve tissue-specific isoenzyme encoded by the GLUD1 and the
GLUD2 gene, respectively (5-8). GLUD1 contains
13 exons and is located on the 10th chromosome, whereas the
GLUD2 gene lacks introns and is X-linked. Mammalian GDH is
shown to be allosterically regulated by diverse compounds, such as
purine nucleotides, steroid hormones, etc (1). GDH regulation is of
particular biological importance as exemplified by observations showing
that regulatory mutations of the GLUD1 GDH are associated
with clinical manifestations in children (9).
Although the two GDH isoenzymes are highly homologous (showing a 97%
amino acid identity), they differ markedly in their regulatory properties (8, 10). Thus, while the GLUD1-derived GDH is sensitive to GTP inhibition, the GLUD2 GDH is resistant to
this compound. In contrast, the GLUD2 GDH is much more
sensitive to allosteric activation by ADP or L-leucine than
the GLUD1-derived enzyme (10). In addition, there are
significant differences between the two isoforms with respect to the
Km values for the substrates of the enzyme.
Because the GLUD1- and GLUD2-derived polypeptides
share in their mature form all but 15 of their 505 amino acids, these
functional differences must arise from amino acid residues that are not
common between the two isoenzymes. Our objective is to identify by
mutagenesis of the GLUD1 gene these critical residues. In
this study, we selected three such residues (Gly-456, Arg-470, and
Asn-498) located in the C-terminal region, which is thought to be part
of the regulatory domain of mammalian GDH (11). Using site-directed
mutagenesis, we created three GLUD1 mutants, each containing
one of these amino substitutions. In each of these sites, the amino
acid residue present in the GLUD2 GDH replaced the
corresponding amino acid of the GLUD1 enzyme. The mutated
cDNAs were expressed in Sf21 cells, and the obtained mutant
GDH isoproteins were purified to homogeneity and studied with respect
to their kinetic and regulatory characteristics. Results showed that
substitution of Ala for Gly at position 456 (but not substitution of
His for Arg-470 or Ser for Asn-498) of the GLUD1 GDH
markedly attenuated GTP inhibition and abolished the cooperative
behavior of the enzyme. The G456A substitution did not affect the
allosteric activation of the mutant GDH by ADP or its kinetic
properties as determined in the absence of allosteric inhibitors. The
structural, functional, and evolutionary implications of these findings
are discussed.
Materials--
Sf21 cells and the baculovirus expression
vectors were obtained from Invitrogen. The media for the
Sf21 insect cells and fetal calf serum were obtained from
Invitrogen. Modified baculovirus (BaculoGold) was obtained from BD
PharMingen (San Diego, CA). NADPH, ADP, GTP (lithium salt), and bovine
liver glutamate dehydrogenase were from Roche Molecular Biochemicals
(Mannheim, Germany). Glutamic acid (monosodium salt) was from Sigma.
Phenyl-Sepharose high performance was from Amersham Biosciences and
hydroxyapatite Bio-Gel HT was from Bio-Rad (Hercules, CA).
Site-directed Mutagenesis of the GLUD1 cDNA--
A
GLUD1 cDNA, cloned in pBSKII+ vector, was mutagenized at
specific sites (Fig. 1) using the Gene
Editor Mutagenesis system according to the manufacturer's protocol
(Promega, Madison, WI). Mutagenic oligonucleotides (25-30 bp in
length) were phosphorylated and annealed to the GLUD1
template by heating the reaction mixture at 75 °C and then by slowly
cooling it (1.5 °C/min) to 37 °C. The annealing reaction also
contained primers (provided by the manufacturer) designed to mutate the
Subcloning in pVL1393--
The mutated GLUD1 cDNA
was cleaved from the pBSKII+ vector using BamHI and
PstI restriction endonucleases and ligated to the baculovirus transfer vector pVL1393. The ligation products were used to
transform the JM109 strain of E. coli. The proper
orientation of the insert was verified by sequencing. The subcloned
mutated GLUD1 gene was bidirectionally sequenced in its
entire length to confirm the presence of the desired mutation and
exclude incidental DNA alterations induced during the above mutagenesis
steps. DNA sequencing was carried out using the LI-COR 4200 system
(LI-COR, Lincoln, Nebraska).
Expression of Recombinant Proteins--
Mutated GLUD1
cDNAs, along with the wild type GLUD1 cDNA (used
here as a control for protein expression and enzymatic analysis), were
expressed in Sf21 cells using the baculovirus expression system
as previously described (7, 10). Cells of the insect Spodoptera
frugiperda (Sf21) were co-transfected with the plasmid DNA
(pVL1393 vector containing the GLUD1 insert) and modified baculovirus DNA (BaculoGold; BD PharMingen) and incubated at 27 °C
for 4-5 days. The virus was amplified by two to three rounds of
infection. The cultured cells were harvested 5 days postinfection and
used for extracting the recombinant GDH proteins. For this, the
cultured cells were homogenized in a buffer containing 0.05 M Tris HCl, pH 7.4, 1% Triton X-100, 0.1 mM
phenylmethylsulfonyl fluoride, and 0.5 M NaCl. The
resulting whole homogenate was centrifuged at 7000 g at
4 °C for 10 min, and the supernatant was used for studies employing
crude extracts. Protein determination was done using the Lowry method
(12). Recombinant baculovirus-containing media were used for isolating
the viral DNA. Segments of this DNA, containing the corresponding
insert were PCR-amplified and sequenced to verify that the desired
mutation was present.
Enzyme Purification--
GDH was purified from Sf21 cell
extracts and from human liver obtained at autopsy. About 1 g of
liver tissue and 200 × 106 infected Sf21 cells
were used for enzyme purification, which was carried out by
modification of our previously published method (13). The tissues were
subjected to two to three cycles of freeze thaw and homogenized
(5-10% w/v) in 10 mM Tris-HCI, pH 7.4, buffer containing
0.1 mM EDTA, 0.5 M NaCl, 1% Triton X-100, and
0.1 mM phenylmethylsulfonyl fluoride. A 30-55% ammonium
sulfate (AS) cut obtained from these extracts was resuspended in 50 mM Tris-HCI, pH 6.0, buffer containing 15% AS, loaded on a
hydrophobic interaction column packed with phenyl-Sepharose high
performance (Amersham Biosciences), and equilibrated with the same
buffer. The column was eluted with a double gradient of decreasing
concentration of AS (15-0%) and increasing concentration of ethylene
glycol (0-90%). Eluted GDH was precipitated with 60% AS and passed
again through the same phenyl-Sepharose column. Because the G456A
mutant has decreased affinity for GTP, we did not employ a GTP binding column (13). Instead, we used hydroxyapatite chromatography as
previously described (14). For this, fractions from the hydrophobic interaction column containing GDH activity were dialyzed (at 4 °C)
against several changes of 100 mM Tris-HCl, 200 mM KCl, pH 7.15, buffer and loaded into the hydroxyapatite
column (14). The column was eluted with a gradient of 10-400
mM sodium phosphate buffer, pH 7.4. Purified GDH was used
for enzyme assays and for studying its electrophoretic mobility by
SDS-PAGE. The latter was done using the Laemmli procedure (15).
Enzyme Assays, Kinetic, and Allosteric Regulation
Studies--
Enzyme activity was assayed spectrophotometrically (at
340 nm) in the direction of reductive amination of
Kinetic analyses were performed to determine the Michaelis-Menten
constant (Km) for
Regulation of the human recombinant GDHs by GTP was studied essentially
as previously described (10) by adding this compound to the reaction
mixture at various concentrations (0.025-1000 µM, final
concentrations) while keeping the other substrates constant. Also, GTP
inhibition was studied in the presence of ADP (0.1 or 1 mM,
final concentrations). To study the allosteric activation of
recombinant GDHs by ADP, this compound was added to the reaction mixture at various concentrations (varying from 0.01 to 1 mM), while the concentration of the other substrates was
kept constant as indicated above.
Statistical Analyses--
All statistical analyses on the
obtained data and plotting were performed by the use of the Origin
Program (MicroCal Software, Northampton, MA). Km and
Vmax values were calculated by application of
the weighted hyperbolic fit method in the Hyper program (Dr. J. S. Easterby, Dept. of Biochemistry, University of Liverpool, Liverpool,
UK). Differences in kinetic and allosteric behavior were evaluated
using Student's t test. IC50 and
SC50 values were determined graphically. The Hill plot
coefficients for GTP inhibition were calculated according to the method
discussed by Cornish-Bowden (16). Results were confirmed by the use of the Leonora program (17). Studies of the structural models of bovine
GDH were performed with the use of the RasMol© (version 2.7.1.1, R. Sayle), Swiss-PDBviewer© (version 3.7.b2, N. Guex) and Quanta
(Accelerys Inc.) programs.
Production of Recombinant Mutant and Wild Type
GDHs--
Expression of the G456A, R470H, and N498S GLUD1
mutants and the wild type GLUD1 gene in Sf21 cells
produced GDH proteins capable of catalyzing the reversible
intercoversion of glutamate to
Enzyme assays, carried out with the use of either NADH or NADPH as
cofactors, revealed that the non-infected host insect cells contained
endogenous GDH showing an absolute specificity for NADH in accordance
with results of previous studies (7). In contrast, the
mammalian-expressed enzymes are capable of using both cofactors. Because non-infected insect cells showed zero GDH activity when assayed
with the use of NADPH, all enzyme assays of extracts of Sf21
cells infected with recombinant baculovirus were done in the presence
of NADPH. This permitted the study of the recombinant human enzymes in
crude extracts without the interference of the endogenous insect
GDH.
Allosteric Regulation of Mutant and Normal GLUD1 GDHs--
Study
of the allosteric properties of the produced mutant GDHs (G456A, R470H,
and N498S mutants), carried out in crude tissue extracts, revealed that
only the G456A mutant exhibited a marked resistance to GTP inhibition
(Fig. 2). Under baseline conditions, the
IC50 for GTP inhibition was about
15-fold higher for the mutant protein
(2.8 µM) as compared with the wild type GLUD1
GDH (0.19 µM) (Table I and Fig.
3A). Similar results were
obtained when GTP inhibition was studied using reaction mixtures of
different pH values (7.0-8.0) (data not shown). Also, the differences
in GTP sensitivity between the G456A mutant and the normal
GLUD1-derived GDH persisted when GTP inhibition was studied
in the presence of ADP (0.1 and 1.0 mM, final
concentrations) (Table I and Figs. 2 and 3B). In addition,
the G456A mutation abolished the cooperative behavior of the enzyme
either in the presence or absence of ADP. As shown in Figs. 2 and 3,
the GTP inhibition of the G456A mutant lacked the characteristic
sigmoidal curve of the wild type GLUD1 GDH. Hill plot
analysis of the data showed that the Hill coefficient (HC) for GTP
inhibition, which for the wild type GLUD1 was 2.09 ± 0.11
In contrast to the G456A mutation, substitution of His for Arg-470 or
Ser for Asn-498 did not affect the allosteric regulation of the enzyme
by GTP. The IC50 for GTP inhibition for the two mutant GDHs
was comparable with that of the wild type GLUD1-derived GDH
(Table I, Fig. 3). In addition, the GTP inhibitory curve for both
mutants was as sigmoidal as that of the wild type
GLUD1-derived GDH (Fig. 3). Hill plot analyses confirmed
that GTP cooperative binding for the R470H and N498S mutants was
similar to that for the GLUD1 GDH (Table I and Fig. 3).
Substitution of Ala for Gly-456 did not alter the activation pattern of
mutant GDHs by ADP. The SC50 values (± S.E.) for the G456A
mutant (25.42 ± 2.6 µM) were similar to that of the
wild type GLUD1 GDH (24.27 ± 4.12 µM).
Comparable SC50 values were also obtained for the R470H
(24.66 ± 2.69 µM) and for the N498S mutant
(23.41 ± 2.63 µM).
Analyses of Purified Mutant and Normal Human GDHs--
The G456A
mutant and the wild type recombinant GLUD1 human GDH were
studied further after they were purified from cell extracts. As an
additional control we used the endogenous human enzyme purified from
human liver. Consistent with results of our previous studies (13),
about 40-50% of the GDH activity present in the crude tissue extracts
was recovered in the purified fractions.
SDS-PAGE analysis of GDH-positive fractions eluted from the
hydroxyapatite column revealed that the enzyme was more than 95% pure
(Fig. 4). As shown in Fig. 4, the
molecular mass of the G456A mutant was identical to that of the
recombinant wild type GLUD1-derived GDH and that of the
endogenous mature human liver enzyme. Human liver is known to express
the GLUD1 gene only (7). The purified human GDHs were
slightly larger than the commercially available bovine liver GDH used
as a marker (Fig. 4). This is consistent with sequencing data showing
the bovine liver enzyme is four amino acids shorter than the human GDHs
(18, 19).
The GDH-specific activity (measured at 8.0 mM
Kinetic analyses revealed that the Km values for
GTP inhibition studies performed with the use of the three purified
enzymes confirmed the above described data on crude extracts by showing
that the purified G456A mutant was markedly resistant to GTP inhibition
(IC50 ± S.E. = 121.35 ± 14.89 µM GTP
determined in the presence of 1 mM ADP) as compared with
the wild type recombinant GLUD1 enzyme (IC50 = 12.95 ± 0.46 µM GTP). The endogenous human liver
GDH was as sensitive to GTP inhibition (IC50 = 15.57 ± 0.57) as the recombinant normal GLUD1 enzyme. Hill
analyses also confirmed that GTP inhibition of the purified G456A
mutant lacked the cooperativity (HC ± S.E. = 0.99 ± 0.07) shown by the purified recombinant wild type GLUD1 GDH
(HC = 2.15 ± 0.16) and the purified human liver enzyme
(HC = 2.17 ± 0.06)
Structural Models--
Study of the structure of mammalian
GDH based on x-ray crystallography of bovine liver GDH (11)
suggests that Gly-456 of the human GLUD1 enzyme (corresponds
to Gly-452 of the bovine protein) lies in a tightly packed region of
the molecule (Figs. 5 and 6). Modeling of
the introduced Ala-456 side chain suggests that this chain may be in
steric clash with the side chain of Phe-387 of the mutant enzyme
(corresponds to Phe-383 of the bovine enzyme) (Fig. 5). The estimated
distance between Ala-456 and Phe-387 is ~2.8 Å. This is short enough
to indicate a steric clash that may alter the conformation of the
Phe-387 side chain, which in turn may affect the nearby Leu-401
(corresponds to Leu-397 of the bovine GDH) side chain from a
neighboring subunit. Another steric clash (2.3 Å) apparent from this
model is between the C To study structure-function relationships in human glutamate
dehydrogenase, we performed site-directed mutagenesis in the C-terminal
region of the GLUD1 gene. Three residues (Gly-456, Arg-470,
and Ser-498) that are different in the GLUD1 as compared with the GLUD2 gene were selected for these studies (Fig.
1). Results showed that replacement of Gly by Ala at site 456 markedly attenuates GTP inhibition and abolishes the cooperative behavior of the enzyme without affecting its kinetic properties (in the absence
of allosteric inhibitors). In contrast, substitution of His for Arg-470
or substitution of Ser for Asn-498 did not alter significantly either
the allosteric regulation or the catalytic properties of the enzyme.
Our recombinant human GDHs are processed in the cultured insect cells
in a manner similar to that of the mammalian GDH, which involves
removal of the 53-amino acid-long leader sequence predicted by the
GLUD1 cDNA (5, 8). Expressed human
GLUD1-derived recombinant proteins purified from our cell
extracts, as done here, show the same molecular mass as the mature
human protein (Fig. 4) and an N-terminal amino acid sequence
(Ser-Glu-Ala-Val-Ala ... ) identical to that obtained by
sequencing of GDH purified from human liver (7, 19).
Cho et al. (20) recently expressed in E. coli
bacterial cells a synthetic human GLUD1 gene lacking the
sequences that predict the leader peptide. They produced a recombinant
GDH protein that had at the N terminus five additional amino acids,
which were subsequently removed using the factor Xa. Lee et
al. (21) have also used this system to identify Lys-450 as a site
for GTP binding. The Gly-456 site studied here lies about a
one-and-a-half- Studies based on chemical modification of bovine brain GDH have
indicated that Gly-456 of the human GLUD1 GDH (corresponds to Gly-452 of bovine sequence) lies in the vicinity of the GTP binding
domain (22). Structural models of mammalian GDH derived from x-ray
crystallographic studies, have suggested that Gly-456 belongs to the
In its tertiary form, GDH is a hexameric molecule composed of two
trimers. Each of the three polypeptide chains of the trimer includes an
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-ketoglutarate using NAD(H) or NADP(H) as cofactors (1). The mature
GDH protein is composed of six identical subunits consisting of 505 amino acids each. The enzyme is thought to play a key role in cellular metabolism and energy homeostasis (2). In the pancreatic
cells, GDH
is thought to be involved in insulin secretion mechanisms, whereas in
the nervous system the enzyme may play a role in the metabolism of
neurotransmitter glutamate and in neurodegenerative processes (3,
4).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-lactamase gene of the pBSKII+ vector. The plasmid was then
amplified by T4 DNA polymerase (nicks were ligated by T4 DNA ligase)
and used to transform the BMH 71-18 mutS strain of
Escherichia coli (to prevent repair of the newly synthesized
strand by the microorganism). The cells were grown in the
presence of an appropriate antibiotic selection mix; plasmid DNA was
isolated and used to transform the JM109 strain of E. Coli.
Clones containing plasmids with the desired mutations were selected by
restriction digestion analysis and by DNA sequencing.
![]()
View larger version (9K):
[in a new window]
Fig. 1.
Schematic representation of the C-terminal
region of GLUD1 and GLUD2 GDHs and of
the three mutants (G456A, R470H, N498S). Dots indicate
amino acid residues of the GLUD2 and the mutant GDHs that
are identical to those of the wild type GLUD1-derived
enzyme.
-ketoglutarate (10). The reaction mixture of 1 ml contained 50 mM
triethanolamine buffer, pH 8.0, 100 mM ammonium acetate,
100 µM NADPH, and 2.6 mM EDTA. NADH was used
instead of NADPH only to test the activity of the endogenous insect
cell GDH. Enzyme reaction was initiated by adding
-ketoglutarate to
8 mM (except as indicated). Initial rates (enzyme velocity
during the first 30 s after initiation of the reaction) were
recorded. Wild type and mutant GLUD1 proteins were studied
in parallel.
-ketoglutarate and NADPH.
Several sets of experiments were performed for each purified enzyme. In each of these experiments,
-ketoglutarate varied from 0.4 to 8.0 mM, while ADP concentration was kept constant at 0 (base
line), 25, or 250 µM. NADPH varied from 10 to
100 µM in the absence of ADP.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-ketoglutarate in the presence of
either NAD(H) or NADP(H). The expressed proteins were about 5-fold
enriched over the endogenous insect cell GDH (data not shown).
Baculovirus DNA was isolated from culture media of infected cell
cultures and sequenced. Results confirmed that the desired mutation for
the corresponding mutant GDHs was present in the virus shed by the
infected cells.
2.51 ± 0.14, changed to values indicative of non-cooperative behavior for the G456A mutant GDH (HC = 1.07 ± 0.04
1.30 ± 0.07) (Table I).

View larger version (11K):
[in a new window]
Fig. 2.
GTP inhibition of the recombinant
G456A mutant GDH and the effect of ADP. Enzyme assays were
performed in the direction of reductive amination of
-ketoglutarate
in the presence of increasing concentrations of GTP. ADP concentration
was kept constant at 0 mM (No Additions), 0.1, and 1 mM. Data points represent mean values of at least two
experimental determinations and are expressed as percentage of baseline
activity obtained in the absence of GTP. ADP displaces the GTP
inhibition curve of the G456A mutant to the right, as is the case for
the normal enzyme. However, in comparison to the normal
GLUD1-derived GDH, IC50 values for GTP
inhibition are 8-15 times higher and the curve is rather hyperbolic
instead of sigmoidal.
Allosteric inhibition of mutant and wild type GLUD1-derived GDHs by GTP
in crude extracts

View larger version (12K):
[in a new window]
Fig. 3.
Comparison of GTP inhibition curves of
G456A, R470H, and N498S mutant GDHs and the wild type
GLUD1-derived GDH (GLUD1).
Data points represent mean values of at least two
experimental determinations and are expressed as percentage of baseline
activity (no GTP added). GDH activity was measured in the direction of
reductive amination of
-ketoglutarate in the presence of increasing
concentrations of GTP. A, GTP inhibitory curves for the four
recombinant enzymes obtained in the absence of ADP. B, GTP
inhibitory curves for the four recombinant enzymes obtained in the
presence of 0.1 mM ADP. Under both conditions, the G456A
mutant is resistant to GTP concentrations that render the wild type GDH
essentially inactive. The R470H and the N498S mutant GDHs retain the
allosteric properties of the wild type enzyme.

View larger version (137K):
[in a new window]
Fig. 4.
12% SDS-PAGE analysis of purified human
GDHs. HLiv, GDH purified from human liver;
G456A, expressed G456A mutant GDH; GL1, expressed
wild type GLUD1-derived GDH; MW, molecular weight
marker proteins; BLiv, bovine liver GDH.
-ketoglutarate and in the presence of 1 mM ADP) of
the purified G456A mutant (133.97 µmol of NADPH
oxidized·min
1·mg protein
1) was
comparable with that of the recombinant wild type
GLUD1-derived GDH (130.50 µmol of NADPH
oxidized·min
1·mg protein
1). Also, the
endogenous human liver GDH gave a similar GDH-specific activity (124.56 µmol of NADPH oxidized·min
1·mg
protein
1).
-ketoglutarate and for NADPH for the purified G456A mutant were similar to those for the purified recombinant wild type
GLUD1 GDH and for the purified endogenous human liver enzyme
(Table II). In addition, the maximum
velocities (Vmax) of the three purified human
GDHs were comparable (Table II).
Kinetic properties of purified mutant and wild type GLUD1-derived GDHs
of Ala-456 and the carbonyl oxygen of residue
452 in the human enzyme (corresponds to residue 448 in the bovine
sequence). This clash occurs assuming that the main chain angles do not
change after replacement of Gly-456 with Ala. The proximity of these
residues to the GTP binding site is shown in Fig. 5.

View larger version (64K):
[in a new window]
Fig. 5.
Molecular model of mammalian GDH.
A, ribbon diagram of one trimer of the GDH homohexamer based
on x-ray crystallographic structure of bovine GDH (11) showing the
bound GTP (green) and the two mutations (red).
The amino acid numbering of the bovine enzyme (11) is retained. Each of
the three subunits is painted in a different color (green,
blue, and yellow). B, close
up of the G452A (corresponds to G456A of the human GLUD1
GDH) mutation site. The dotted lines indicate possible
steric clashes. C, close up of the N494S (corresponds to
N498S of the human GLUD1 GDH) mutation site. This analysis
was performed by Dr. Michael Karpusas, a Scientist at Biogen and an
assistant professor of biochemistry, University of Crete.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-helix turn away from Lys-450, with the side chain of
the former amino acid residue protruding out of the
-helix in the
opposite direction than the side chain of the latter according to the
proposed structural models (11).
-helix of the GDH protein that comes into direct contact with GTP
(11, 23, 24). Specifically, Gly-456 is located at the base ("hinge
region") of an "antenna-like" region of GDH, which is
thought to be important for the interaction between the subunits of the
catalytically active enzyme (11).
-helix to which GTP binds, as noted above. Gly-456 lies exactly at
the point where the GTP-binding
-helix of one subunit comes in
direct contact with the antenna-like region of the other (Figs. 5 and
6). As described under "Results,"
introduction of Ala-456 side chain occurs in a tightly packed region of
the molecule, and this may lead to steric clashes with other side chains (Fig. 5). These disturbances may impair the ability of the
antenna to facilitate intersubunit communication, a process that may be
essential for GTP inhibition and cooperative effects (11).

View larger version (41K):
[in a new window]
Fig. 6.
Location of the introduced
mutations. Shown is a cartoon diagram of the C-terminal
region of the three subunits of one of the two trimers that compose the
GDH hexamer based on x-ray crystallographic data from bovine liver GDH
(11). For simplicity, the N-terminal region of these subunits and the
other trimer are omitted. The amino acid numbering of the bovine enzyme
(11) is retained. Each of the three subunits is painted in a different
color (green, blue, and light
green, respectively). Gly-452 (corresponds to Gly-456 in the
human) is shown in red, Arg-466 (corresponds to Arg-470 in
the human) is shown in purple, and Asn-494 (corresponds to
Asn-498 in the human) is shown in orange, irrespectively of
the subunit they belong to. The three bound GTP molecules (one for each
subunit) are depicted as ball and stick models in yellow. In
the center (asterisk) is shown the interaction of the hinge
GTP binding
-helix of one subunit (blue) with the antenna
region of the other subunit (green). Gly-452 (corresponds to
Gly-456 in the human GLUD1 GDH) lies at this point of
interaction.
In contrast to the G456A mutation, substitution of His for Arg-470 or of Ser for Asn-498 did not affect the properties of the GLUD1-derived GDH. Arg-470 is located on the surface of the protein (Fig. 6) where it does not appear to interact with other amino acids. Also, Asn-498 is not located in a tightly packed region of the GDH molecule; its only possible interaction is with Arg-48 (corresponds to Arg-44 in the bovine) (Fig. 5), and as such, the present results suggest that this interaction may not be essential for enzymatic function.
Stanley et al. (9) have described mutations affecting the regulatory domain of the GLUD1-derived GDH in children with the hyperinsulinism-hyperamonemia syndrome. Additional cases have been described by these and other investigators (25-30). GTP inhibition of the mutant proteins, expressed in COS cells or in cultured patient lymphoblasts, was found to be attenuated (the IC50 increased 2-6-fold). The Gly-456 residue studied here, lies immediately downstream of the amino acid residues encoded by the 11th and 12th exons of the GLUD1 gene and which are altered by these spontaneous mutations.
There is evidence that in the human the GLUD1 gene (located on the 10th chromosome) has been retro-posed to the X chromosome, where it gave rise to the GLUD2 gene through random mutations and natural selection. Previous functional analyses of the two GDH-specific genes have suggested that the GLUD2 gene might have adapted to particular needs of the nervous system where it is specifically expressed (3). The nerve tissue-specific GDH (GLUD2-derived) that is resistant to GTP inhibition differs at its C-terminal region in three positions (amino acid residues 456, 470, and 498) from the GLUD1 GDH, which is GTP-sensitive (Fig. 1). Our functional analysis showed that only substitution of Ala for Gly-456 is sufficient to confer resistance to GTP. This resistance may permit the nerve tissue-specific GDH to function in the GTP-rich environment that prevails in the nervous tissue.
The present data, however, indicate that the presence of Ala instead of
Gly at position 456 in the GLUD2 GDH is not sufficient to
explain other functional differences that exist between this and the
GLUD1 GDH. These include: a diminished catalytic activity of
GLUD2 isoenzyme in the absence of allosteric activators and a marked sensitivity of this isoenzyme to ADP and to
L-leucine activation (8, 10). Hence, additional studies are
needed to identify the residues responsible for these functional
properties unique to the nerve tissue-specific GLUD2
GDH.
| |
ACKNOWLEDGEMENTS |
|---|
We are deeply indebted to Dr. Michael Karpusas for performing the structural analysis of the mutations. We also thank Dr. E. Michalodimitrakis, Dr. P. Shashidharan, Irene Skoula, and G. Vrentzos for their help in these studies.
| |
FOOTNOTES |
|---|
*
This work was supported by the Association for Research and
Treatment of Neurological Disorders of Crete
"E

" and the Training Grant "Maria
Manasaki" by the University of Crete (to I. Z.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Neurology,
University of Crete, School of Health Sciences, Section of Medicine,
71500 Heraklion, Crete, Greece. Tel.: 30-810-394647/8; Fax:
30-810-394839; E-mail: plaitak@med.uoc.gr.
Published, JBC Papers in Press, April 11, 2002, DOI 10.1074/jbc.M200022200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: GDH, glutamate dehydrogenase; AS, ammonium sulfate; HC, Hill coefficient.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Smith, E. L., Austin, B. M., Blumenthal, K. M., and Nyc, J. F. (1975) in The Enzymes (Boyer, P. D., ed) , pp. 293-367, Academic Press, New York |
| 2. | Hudson, R. C., and Daniel, R. M. (1993) Comp. Biochem. Physiol. 106, 767-792 |
| 3. | Plaitakis, A., and Zaganas, I. (2001) J. Neurosci. Res. 66, 899-908[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Plaitakis, A., Berl, S., and Yahr, M. D. (1984) Ann. Neurol. 15, 144-153[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Mavrothalassitis, G.,
Tzimagiorgis, G.,
Mitsialis, A.,
Zannis, V. I.,
Plaitakis, A.,
Papamatheakis, J.,
and Moschonas, N. K.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
3494-3498 |
| 6. | Michaelides, T. M., Tzimagiorgis, G., Moschonas, N. K., and Papamatheakis, J. (1993) Genomics 16, 150-160[CrossRef][Medline] [Order article via Infotrieve] |
| 7. |
Shashidharan, P.,
Michaelides, T. M.,
Robakis, N. K.,
Kretsovali, A.,
Papamatheakis, J.,
and Plaitakis, A.
(1994)
J. Biol. Chem.
269,
16971-16976 |
| 8. | Shashidharan, P., Clarke, D. D., Ahmed, N., Moschonas, N., and Plaitakis, A. (1997) J. Neurochem. 68, 1804-1811[Medline] [Order article via Infotrieve] |
| 9. |
Stanley, C. A.,
Lieu, Y. K.,
Hsu, B. Y.,
Burlina, A. B.,
Greenberg, C. R.,
Hopwood, N. J.,
Perlman, K.,
Rich, B. H.,
Zammarchi, E.,
and Poncz, M.
(1998)
N. Engl. J. Med.
338,
1352-1357 |
| 10. | Plaitakis, A., Metaxari, M., and Shashidharan, P. (2000) J. Neurochem. 75, 1862-1869[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Peterson, P., and Smith, T. J. (1999) Structure 7, 769-782[Medline] [Order article via Infotrieve] |
| 12. |
Lowry, O. H.,
Rosebrough, N. J.,
Far, A. L.,
and Randall, R. J.
(1951)
J. Biol. Chem.
193,
265-275 |
| 13. |
Hussain, M. M.,
Zannis, V.,
and Plaitakis, A.
(1989)
J. Biol. Chem.
264,
20730-20735 |
| 14. | Colon, A. D., Plaitakis, A., Perakis, A., Berl, S., and Clarke, D. D. (1986) J. Neurochem. 46, 1811-1819[Medline] [Order article via Infotrieve] |
| 15. | Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Cornish-Bowden, A. (1979) Fundamentals of Enzyme Kinetics , pp. 147-176, Butterworth, London |
| 17. | Cornish-Bowden, A. (1995) Analysis of Enzyme Kinetic Data , pp. 133-189, Oxford University Press, New York |
| 18. |
Moon, K.,
and Smith, E. L.
(1973)
J. Biol. Chem.
248,
3082-3088 |
| 19. |
Julliard, J. H.,
and Smith, E. L.
(1979)
J. Biol. Chem.
254,
3427-3438 |
| 20. | Cho, S. W., Yoon, H. Y., Ahn, J. Y., Lee, E. Y., and Lee, J. (2001) Eur. J. Biochem. 268, 3205-3213[Medline] [Order article via Infotrieve] |
| 21. |
Lee, E. Y.,
Yoon, H. Y.,
Ahn, J. Y.,
Choi, S. Y.,
and Cho, S. W.
(2001)
J. Biol. Chem.
276,
47930-47936 |
| 22. | Cho, S. W., Ahn, J. Y., Lee, J., and Choi, S. Y. (1996) Biochemistry 35, 13907-13913[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Peterson, P., Pierce, J., and Smith, T. J. (1998) J. Struct. Biol. 120, 73-77 |
| 24. | Smith, T. J., Peterson, P., Schmidt, T., Fang, J., and Stanley, C. (2001) J. Mol. Biol. 307, 707-720[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Yorifuji, T., Muroi, J., Uematsu, A., Hiramatsu, H., and Momoi, T. (1999) Hum. Genet. 104, 476-479[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Miki, Y., Taki, T., Ohura, T., Kato, H., Yanagisawa, M., and Hayashi, Y. (2000) J. Pediatr. 136, 69-72[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Santer, R., Kinner, M., Passarge, M., Superti-Furga, A., Mayatepek, E., Meissner, T., Schneppenheim, R., and Schaub, J. (2001) Hum. Genet. 108, 66-71[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | De Lonlay, P., Benelli, C., Fouque, F., Ganguly, A., Aral, B., Dionisi-Vici, C., Touati, G., Heinrichs, C., Rabier, D., Kamoun, P., Robert, J., Stanley, C., and Saudubray, J. (2001) Pediatr. Res. 50, 353-357[Medline] [Order article via Infotrieve] |
| 29. | Stanley, C., Fang, J., Kutyna, K., Hsu, B. Y. L., Ming, J., Glaser, B., and Poncz, M. (2000) Diabetes 49, 667-673[Abstract] |
| 30. |
MacMullen, C.,
Fang, J.,
Hsu, B. Y. L.,
Kelly, A., De,
Lonlay-Debeney, P.,
Saudubray, J. M.,
Ganguly, A.,
Smith, T.,
and Stanley, C.
(2001)
J. Clin. Endocrinol. Metab.
86,
1782-1787 |
This article has been cited by other articles:
![]() |
M.-M. Choi, E.-A Kim, S.-J. Yang, S. Y. Choi, S.-W. Cho, and J.-W. Huh Amino Acid Changes within Antenna Helix Are Responsible for Different Regulatory Preferences of Human Glutamate Dehydrogenase Isozymes J. Biol. Chem., July 6, 2007; 282(27): 19510 - 19517. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Zaganas, C. Spanaki, M. Karpusas, and A. Plaitakis Substitution of Ser for Arg-443 in the Regulatory Domain of Human Housekeeping (GLUD1) Glutamate Dehydrogenase Virtually Abolishes Basal Activity and Markedly Alters the Activation of the Enzyme by ADP and L-Leucine J. Biol. Chem., November 22, 2002; 277(48): 46552 - 46558. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |